__timestamp | Catalent, Inc. | Perrigo Company plc |
---|---|---|
Wednesday, January 1, 2014 | 1229100000 | 2613100000 |
Thursday, January 1, 2015 | 1215500000 | 2891500000 |
Friday, January 1, 2016 | 1260500000 | 3228800000 |
Sunday, January 1, 2017 | 1420800000 | 2966700000 |
Monday, January 1, 2018 | 1710800000 | 2900200000 |
Tuesday, January 1, 2019 | 1712900000 | 3064100000 |
Wednesday, January 1, 2020 | 2111000000 | 3248100000 |
Friday, January 1, 2021 | 2646000000 | 2722500000 |
Saturday, January 1, 2022 | 3188000000 | 2996200000 |
Sunday, January 1, 2023 | 3216000000 | 2975200000 |
Monday, January 1, 2024 | 3428000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, understanding cost trends is crucial. Catalent, Inc. and Perrigo Company plc, two giants in the sector, have shown distinct trajectories in their cost of revenue from 2014 to 2023. Catalent's cost of revenue has surged by approximately 179% over this period, reflecting its aggressive expansion and increased production capabilities. In contrast, Perrigo's costs have remained relatively stable, with a modest increase of around 14%, indicating a more conservative growth strategy.
These trends offer a window into the strategic priorities of each company, with Catalent focusing on expansion and Perrigo on maintaining operational efficiency.
Cost of Revenue Trends: AbbVie Inc. vs Catalent, Inc.
Analyzing Cost of Revenue: Merck & Co., Inc. and Perrigo Company plc
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Catalent, Inc.
Cost Insights: Breaking Down GSK plc and Catalent, Inc.'s Expenses
Cost Insights: Breaking Down GSK plc and Perrigo Company plc's Expenses
Cost Insights: Breaking Down Biogen Inc. and Catalent, Inc.'s Expenses
Cost of Revenue: Key Insights for Biogen Inc. and Perrigo Company plc
Cost of Revenue: Key Insights for United Therapeutics Corporation and Perrigo Company plc
Cost Insights: Breaking Down Catalent, Inc. and Vericel Corporation's Expenses
Catalent, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Perrigo Company plc
Analyzing Cost of Revenue: Perrigo Company plc and Iovance Biotherapeutics, Inc.